| Literature DB >> 34912548 |
.
Abstract
BACKGROUND: This research prioritization aimed to identify major research gaps in maternal, newborn, child and adolescent health (MNCAH) to help mitigate the direct and indirect effects of the COVID-19 pandemic.Entities:
Mesh:
Year: 2021 PMID: 34912548 PMCID: PMC8645217 DOI: 10.7189/jogh.11.04071
Source DB: PubMed Journal: J Glob Health ISSN: 2047-2978 Impact factor: 7.664
Top ten research priority questions on maternal health ranked by research priority score
| Research priorities on maternal health | Research priority score |
|---|---|
| 1. How can the access to postnatal including home-based health services affected by the pandemic be improved (eg, using telemedicine)? | 0.90 |
| 2. In pregnant women with SARS-CoV-2 infection or COVID-19 disease, what are the risk (eg, co-morbidities, co-infection) and determinants (eg, malnutrition, body composition) of adverse maternal and perinatal outcomes (eg, maternal morbidity, stillbirth, etc.)? | 0.89 |
| 3. How has the COVID-19 pandemic affected health-seeking behavior for antenatal care, childbirth, or postnatal care (eg, frequency of visits, birth at health facilities, family planning advice, etc.)? | 0.88 |
| 4. How can the access to maternal and perinatal health services affected by the pandemic be improved? (eg, skilled delivery, telemedicine, use of point of care ultrasound) | 0.87 |
| 5. Is the safety and efficacy of the SARS-CoV-2 vaccine different in pregnant women compared to non-pregnant women? | 0.87 |
| 6. What are the effective drugs/procedures to manage women with COVID-19 disease in the 1st, 2nd, and 3rd trimester of pregnancy? | 0.87 |
| 7. How can the provision of essential maternal and perinatal health commodities affected by the pandemic be improved? | 0.86 |
| 8. In postpartum women with COVID-19, what are the risk and determinants of transmission of SARS-CoV-2 to the newborn by breastfeeding or breastmilk? | 0.85 |
| 9. Are pregnant women with complications such as pregnancy-induced hypertension, pre-eclampsia, gestational diabetes, malnutrition, anemia, HIV-1, and malaria at increased risk of SARS-CoV-2 infection or COVID-19 disease compared to women with uncomplicated pregnancies? | 0.85 |
| 10. What are the risk and determinants of severe disease or death in pregnant women with SARS-CoV-2 infection or COVID-19 disease (eg, sociodemographic, immunological/hormonal, microbiota, nutritional)? | 0.85 |
Top ten research priority questions on newborn health ranked by research priority score
| Research priorities on newborn health | Research priority score |
|---|---|
| 1. What are the most effective treatment strategies for symptomatic newborns with SARS-CoV-2 infection, especially those with respiratory illness? | 0.90 |
| 2. What is the effectiveness of different interventions (eg, maternal hygiene, facemask use, maternal-newborn separation, etc.) to prevent neonatal acquisition of SARS-CoV-2 in the early postnatal period in the hospital and at home while breastfeeding, during skin-to-skin contact or kangaroo mother care, especially if the mother has symptomatic COVID-19 disease? | 0.87 |
| 3. Is SARS-CoV-2 transmissible to healthy infants including newborns of mothers infected with the virus? What are the routes of transmission during in-utero, intrapartum, and postnatal periods (eg, transplacental, contact with virus present in vaginal or fecal secretions during delivery, breastmilk, etc.)? Does the incidence and severity of infection in the newborns differ by the timing, transmission, or mode of delivery (eg, cesarean vs vaginal delivery)? | 0.87 |
| 4. What are the clinical presentations of SARS-CoV-2 infection in newborns? What is the burden of severe COVID-19 disease in newborns? | 0.87 |
| 5. What proportion of newborns infected with SARS-CoV-2 presenting for care with hypoxemia receive oxygen therapy, and what is the case fatality rate in this population? | 0.86 |
| 6. What is the most effective way to prevent the transmission of SARS-CoV-2 to preterm newborns receiving kangaroo mother care? | 0.86 |
| 7. What are the major risk and/or protective factors (eg, breastfeeding, skin-to-skin care or kangaroo mother care, low birth weight, Bacillus Calmette Guerin or other existing vaccinations, HIV-1 exposure, etc.) for the acquisition of SARS-CoV-2 infection or development of COVID-19 disease or severe disease in newborns of SARS-CoV-2 infected mothers? | 0.85 |
| 8. In newborns with severe COVID-19 disease, is the addition of dexamethasone to the standard of care more effective in improving newborn survival compared to the standard of care alone? | 0.85 |
| 9. Which is the most appropriate diagnostic sample for diagnosis of SARS-CoV-2 infection in newborns (eg, oral secretion, nasal swab, fecal swab, cord or peripheral blood, etc.? | 0.84 |
| 10. What is the impact of maternal SARS-CoV-2 infection on newborn health outcomes (eg, intrauterine growth restriction, prematurity, and birth asphyxia), and how can this be mitigated? | 0.83 |
Top ten research priority questions on child and adolescent health ranked by research priority score
| Research priorities on child and adolescent health | Research priority scores |
|---|---|
| 1. How can routine vaccination services for children be sustained/improved during the COVID-19 pandemic? | 0.95 |
| 2. What are the effective and safe strategies for in-class education during the COVID-19 pandemic? What is the attack rate within schools, and what interventions (eg, face masks, physical distancing, hand disinfection/washing, etc.) are effective for prevention of transmission of SARS-CoV-2 in schools, by age/school year and by type of school (eg, day vs boarding)? | 0.94 |
| 3. What are the most effective strategies for communication about the prevention of SARS-CoV-2 infection to adolescents and young adults? | 0.93 |
| 4. What are the protective factors, including breastfeeding/feeding practices, maternal vaccination against severe COVID-19 disease in infants, children, and adolescents (0-19 y), and do these differ by age? | 0.92 |
| 5. What is the impact of comorbidities (eg, asthma, diabetes, undernutrition, overweight or obesity, HIV-1 exposure or HIV-1 infection, etc.) in children and adolescents (0-19 y) with SARS-CoV-2 infection on development of disease and on its clinical severity and outcome? | 0.91 |
| 6. What is the effect of reopening schools on SARS-CoV-2 transmission among different age groups in the general population (based on real-life data)? | 0.91 |
| 7. What is the sensitivity and specificity of SARS-CoV-2 RT-PCR testing in children? | 0.90 |
| 8. What is the impact of the COVID-19 pandemic on essential child health services (both at a community level and facility level)? | 0.90 |
| 9. What are the best risk-stratification tools (eg, Integrated Management of Childhood Illness algorithm, biomarkers, clinical scores, etc.) to triage sick children with suspected SARS-CoV-2 infection or COVID-19 disease, and with sufficiently good performance to predict the severity and outcome? | 0.88 |
| 10. What is the prevalence of SARS-CoV-2 infection in breastfed vs non-breastfed infants? | 0.88 |
Top five research priority questions in cross-cutting or health systems area, ranked by research priority score
| Research priorities in cross-cutting/health system domain | Research priority score |
|---|---|
| 1. What are safe and cost-effective approaches to provide oxygen to pregnant women, newborns, and children who need oxygen in low- and middle-income countries with limited oxygen supply? | 0.93 |
| 2. What are the barriers to the provision of essential reproductive, maternal, newborn, child, and adolescent health services during the COVID-19 pandemic? What are proven health system approaches/solutions that countries have adapted or implemented to ensure continuity of essential reproductive, maternal, newborn, child, and adolescent health services during the COVID-19 pandemic? | 0.93 |
| 3. What are the effective health system adaptations to sustain care-seeking and support or resume high-quality essential services for women, newborns, children, and adolescents in COVID-19 and post-COVID-19 contexts? | 0.91 |
| 4. To what extent are resources (health workers, oxygen support, infection, and prevention control supplies) being diverted from women, newborns, and children or routine services to provide care for COVID-19 disease? | 0.90 |
| 5. What different models have countries taken to adapt or modify health services for maternal and newborn health during the COVID-19 pandemic, and what is the effect of the new adapted or modified or redesigned COVID-19 models of care (eg, remote antenatal and postnatal services replacing in-person contact) on access, coverage, quality of care and outcomes of mothers and newborns, especially for marginalized populations? | 0.88 |